Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial
暂无分享,去创建一个
H. Cohen | C. Gross | G. Lyman | B. Moy | W. Dale | H. Muss | W. Tew | N. Kuderer | A. Chapman | A. Magnuson | R. Freedman | H. Klepin | V. Katheria | T. Wildes | E. Dotan | M. Fenton | M. Sedrak | Jingran Ji | S. Chow | Can‐lan Sun | T. O'Connor
[1] T. Synold,et al. Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Gajra,et al. The Use and Knowledge of Validated Geriatric Assessment Instruments Among US Community Oncologists , 2022, JCO oncology practice.
[3] S. Plumb,et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study , 2021, The Lancet.
[4] M. Fakih,et al. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.
[5] G. Kuchel,et al. Accelerated aging in older cancer survivors , 2021, Journal of the American Geriatrics Society.
[6] C. Nielson,et al. Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis , 2021, The oncologist.
[7] William A. Hammond,et al. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis. , 2020, The Lancet. Oncology.
[8] W. Dale,et al. How Is Geriatric Assessment Used in Clinical Practice for Older Adults With Cancer? A Survey of Cancer Providers by the American Society of Clinical Oncology , 2020, JCO oncology practice.
[9] H. Cohen,et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions , 2020, CA: a cancer journal for clinicians.
[10] J. Unger,et al. Capacity to Provide Geriatric Specialty Care for Older Adults in Community Oncology Practices. , 2020, The oncologist.
[11] Xiaoyi Wang,et al. The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients , 2020, Scientific Reports.
[12] G. Babiera,et al. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. , 2020, JAMA oncology.
[13] Jingmei Li,et al. Impact of deviation from guideline recommended treatment on breast cancer survival in Asia , 2020, Scientific Reports.
[14] S. Mohile,et al. Barriers to clinical trial enrollment of older adults with cancer: A qualitative study of the perceptions of community and academic oncologists. , 2020, Journal of geriatric oncology.
[15] Charles R. Thomas,et al. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. , 2019, JAMA oncology.
[16] J. Sanmugarajah,et al. Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer , 2018, Clinical breast cancer.
[17] A. Deal,et al. Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the Association With Mortality Among Older Adults With Cancer. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] H. Cohen,et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] W. Wood,et al. Geriatric assessment-identified deficits in older cancer patients with normal performance status. , 2015, The oncologist.
[20] A. Deal,et al. Geriatric assessment as an aide to understanding falls in older adults with cancer , 2015, Supportive Care in Cancer.
[21] G. Lyman,et al. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting , 2013, Breast Cancer Research and Treatment.
[22] D. Cutter,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.
[23] V. Coyle,et al. Achieving Optimal Dose Intensity with Adjuvant Chemotherapy in Elderly Breast Cancer Patients: A 10‐Year Retrospective Study in a UK Institution , 2012, The breast journal.
[24] N. Ngamphaiboon,et al. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis , 2012, Medical Oncology.
[25] Supriya G Mohile,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Wildiers,et al. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. , 2011, Critical reviews in oncology/hematology.
[27] Shuangzhe Liu,et al. Regression diagnostics , 2020, Applied Quantitative Analysis for Real Estate.
[28] S. Welch,et al. Relative dose intensity delivered to patients with early breast cancer: Canadian experience. , 2009, Current Oncology.
[29] F. Holmes,et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Thigpen. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer , 2009 .
[31] I. Chirivella,et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients , 2009, Breast Cancer Research and Treatment.
[32] F. Holmes,et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Goodwin,et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] G. Lyman,et al. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy , 2006, Breast Cancer Research and Treatment.
[35] H. Cohen,et al. Developing a cancer‐specific geriatric assessment , 2005, Cancer.
[36] H. Cohen,et al. Developing a cancer-specific geriatric assessment : A feasibility study , 2005 .
[37] Douglas G. Altman,et al. Methodological challenges in the evaluation of prognostic factors in breast cancer , 2004, Breast Cancer Research and Treatment.
[38] G. Lyman,et al. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Gnant,et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] I. Tannock,et al. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma , 2001, Cancer.
[42] L Biganzoli,et al. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? , 2000, European journal of cancer.
[43] J. Chang,et al. Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. , 2000, European journal of cancer.
[44] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[45] D A Berry,et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.
[46] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[47] Emmanuel Lesaffre,et al. Collinearity in generalized linear regression , 1993 .
[48] P. Duffey,et al. The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] W. Hryniuk. Dose intensity: a critique of a critical review. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] W. Hryniuk. Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[52] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. D. Beaumont,et al. Regression Diagnostics — Identifying Influential Data and Sources of Collinearity , 1981 .